Filtros de búsqueda

Lista de obras de Michael Untch

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

artículo científico publicado en 2017

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

artículo científico publicado en 2013

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts

artículo científico publicado en 2015

15. Internationale St.-Gallen-Konsensus-Konferenz: Behandlung des frühen Mammakarzinoms

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

artículo científico publicado en 2013

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

artículo científico publicado en 2007

4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.

artículo científico publicado en 2018

A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance

artículo científico publicado en 2005

A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab

artículo científico publicado en 2005

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

artículo científico publicado en 2016

A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

artículo científico publicado en 2018

ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011.

artículo científico publicado en 2012

ABC3 Consensus Commented from the Perspective of the German Guidelines

artículo científico publicado en 2016

ABC3 Consensus: Assessment by a German Group of Experts

artículo científico publicado en 2016

ABC4 Consensus: Assessment by a German Group of Experts

article

ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.

artículo científico publicado en 2003

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

artículo científico publicado en 2006

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial

artículo científico publicado en 2013

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

artículo científico publicado en 2018

Adherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'

artículo científico publicado en 2008

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

artículo científico publicado en 2015

Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer

artículo científico publicado en 2006

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience

artículo científico publicado en 2013

Anthracycline and trastuzumab in breast cancer treatment

artículo científico publicado en 2004

Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies ⬇️

artículo científico publicado el 20 de febrero de 2009

Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer

artículo científico

Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany

artículo científico publicado en 2016

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer

artículo científico publicado en 2009

Association analysis identifies 65 new breast cancer risk loci.

artículo científico publicado en 2017

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

artículo científico publicado en 2004

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

artículo científico publicado en 2010

Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk.

artículo científico publicado en 2005

Association of prolactin and its receptor gene regions with familial breast cancer.

artículo científico publicado en 2006

Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant.

artículo científico publicado en 2005

Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis

article by Xiang Shu et al published 1 October 2018 in International Journal of Epidemiology

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

article

Breast Cancer during Pregnancy: An Interdisciplinary Approach in Our Institution

artículo científico publicado en 2012

Breast Reconstruction Following Cancer Treatment

artículo científico publicado en 2015

Breast cancer and pregnancy: challenges of chemotherapy

artículo científico publicado en 2008

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study

artículo científico publicado en 2010

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

artículo científico publicado en 2013

Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial

artículo científico publicado en 2004

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

artículo científico publicado en 2014

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.

artículo científico publicado en 2014

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

artículo científico publicado en 2005

Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay

artículo científico publicado en 1993

Chemosensitivity testing in gynecologic oncology--dream or reality?

artículo científico publicado en 2003

Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro

scientific article published on 01 November 1992

Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer ⬇️

artículo científico publicado el 24 de abril de 2008

Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients

artículo científico publicado en 2003

Clinical practice decisions in endocrine therapy

artículo científico publicado en 2010

Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study

artículo científico publicado en 2007

Comparative analyses of bone marrow micrometastases in breast and gastric cancer

artículo científico publicado en 1996

Comparative chemosensitivity profiles in three human breast cancer cell lines with the ATP-cell viability assay

scientific article published on 01 November 1994

Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay

artículo científico publicado en 1992

Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay

artículo científico publicado en 1994

Contextual factors in shared decision making: a randomised controlled trial in women with a strong suspicion of breast cancer

artículo científico publicado en 2009

Current and future role of neoadjuvant therapy for breast cancer

artículo científico

Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast canc

artículo científico publicado en 2002

DNA cell-cycle analysis of cervical cancer by flow cytometry using simultaneous cytokeratin labelling for identification of tumour cells

artículo científico publicado en 1995

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

artículo científico publicado en 2012

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

artículo científico publicado en 2010

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.

artículo científico publicado en 2019

Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.

artículo científico publicado en 2015

Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib.

artículo científico publicado en 2014

Dose-Dense Therapy ⬇️

artículo científico publicado el 28 de abril de 2008

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples

artículo científico publicado en 2001

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).

artículo científico publicado en 2015

Dual HER2 Blockade

artículo científico publicado en 2017

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

artículo científico publicado en 2016

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial

artículo científico publicado en 2016

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

artículo científico publicado en 2008

Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).

artículo científico publicado en 2017

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

artículo científico publicado en 2009

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

artículo científico publicado en 2008

Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients

scientific article published on 01 January 2003

Exemestane in early breast cancer: a review

artículo científico publicado en 2008

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.

artículo científico publicado en 2014

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

artículo científico publicado en 2010

Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element

artículo científico publicado en 2021

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

artículo científico publicado en 2015

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

scientific article published on 18 May 2020

Genome-wide association study of germline variants and breast cancer-specific mortality

artículo científico publicado en 2019

German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients

artículo científico publicado en 2017

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer

artículo científico publicado en 2013

Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

artículo científico publicado en 2020

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

artículo científico publicado en 2017

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

artículo científico publicado en 2015

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

artículo científico publicado en 2013

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

artículo científico publicado en 2013

Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer

artículo científico

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

artículo científico

Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.

artículo científico publicado en 2001

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

artículo científico

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study

artículo científico publicado en 2016

Immunotherapy: new options in breast cancer treatment

artículo científico publicado en 2003

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.

artículo científico publicado en 2015

Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data

artículo científico publicado en 2015

In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms.

artículo científico publicado en 1995

In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines

scientific article published on 01 January 1993

In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines

artículo científico publicado en 1993

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).

artículo científico publicado en 2017

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.

artículo científico publicado en 2016

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

artículo científico publicado en 2010

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

artículo científico publicado en 2010

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer

artículo científico publicado en 2009

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

artículo científico

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

artículo científico publicado en 2003

Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis

artículo científico publicado en 2016

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial ⬇️

artículo científico publicado el 17 de enero de 2012

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

artículo científico publicado en 2012

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

artículo científico publicado en 2014

Lapatinib – Member of a New Generation of ErbB-Targeting Drugs ⬇️

artículo científico publicado el 26 de abril de 2010

Lessons from the neoadjuvant setting on how best to choose adjuvant therapies

artículo científico

Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.

artículo científico publicado en 2007

Limited relevance of the CHEK2 gene in hereditary breast cancer

artículo científico publicado en 2004

Lymph node staging in invasive breast cancer

artículo científico publicado en 2014

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial

artículo científico publicado en 2013

Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment

artículo científico

Maximizing clinical benefit with trastuzumab

artículo científico publicado en 2004

Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors

artículo científico publicado en 2008

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose

artículo científico publicado en 2008

Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients

artículo científico publicado en 2013

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial

artículo científico publicado en 2016

Neoadjuvant Chemotherapy: Early Response as a Guide for Further Treatment: Clinical, Radiological, and Biological ⬇️

artículo científico publicado el 1 de enero de 2011

Neoadjuvant Treatment of Breast Cancer

artículo científico publicado en 2011

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

artículo científico publicado en 2013

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

artículo científico publicado en 2017

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

artículo científico publicado en 2014

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

artículo científico publicado en 2012

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

artículo científico publicado en 2013

Neoadjuvant clinical trials for the treatment of primary breast cancer: the experience of the German study groups

artículo científico publicado en 2012

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

artículo científico publicado en 2010

Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia

artículo científico publicado en 2004

News from the San Antonio Breast Cancer Symposium 2009 ⬇️

artículo científico publicado el 16 de febrero de 2010

Nucleosomes in serum as a marker for cell death

artículo científico publicado en 2001

Nucleosomes in serum of patients with benign and malignant diseases

scientific article published on 01 March 2001

Obstetrical and gynecological writing and publishing in Europe

artículo científico publicado en 2006

Optimal Sequencing of Anti-HER2 Therapy

artículo científico publicado en 2014

Optimal treatment strategies in hormone-responsive early breast cancer: the role of aromatase inhibitors

artículo científico publicado en 2007

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials.

artículo científico publicado en 2018

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials

artículo científico publicado en 2017

Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials

artículo científico publicado en 2015

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

artículo científico publicado en 2014

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar

artículo científico publicado el 8 de marzo de 2011

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin

artículo científico publicado el 7 de marzo de 2011

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups ⬇️

artículo científico publicado el 25 de julio de 2011

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

artículo científico publicado en 2014

Pharmacokinetics and selectivity of aminolevulinic acid-induced porphyrin synthesis in patients with cervical intra-epithelial neoplasia

artículo científico publicado en 1998

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

artículo científico publicado en 2006

Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid

artículo científico publicado en 1999

Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid

artículo científico publicado en 2000

Phyllodes tumour of the breast: clinical follow-up of 33 cases of this rare disease

artículo científico publicado en 2007

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

artículo científico publicado en 2019

Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts

artículo científico publicado en 2011

Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer--a problem still to be solved

artículo científico publicado en 2014

Predictive factors for response to neoadjuvant therapy in breast cancer

artículo científico publicado en 2014

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial

artículo científico publicado en 2012

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

artículo científico publicado en 2012

Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).

artículo científico publicado en 2015

Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.

artículo científico publicado en 2009

Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.

artículo científico publicado en 2013

Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant "Geparquattro" trial

artículo científico publicado en 2017

Prophylactic Surgery: For Whom, When and How?

artículo científico publicado en 2017

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

artículo científico publicado en 2013

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

artículo científico publicado en 2003

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

artículo científico publicado en 2012

Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).

artículo científico publicado en 2017

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

artículo científico publicado en 2001

Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy

artículo científico publicado en 2011

Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents

artículo científico publicado en 2009

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

artículo científico publicado en 2009

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

artículo científico publicado en 2006

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

artículo científico publicado en 2007

Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga.

artículo científico publicado en 2015

Response-guided neoadjuvant chemotherapy for breast cancer.

artículo científico publicado en 2013

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

artículo científico publicado en 2016

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

artículo científico publicado en 2014

Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective

artículo científico publicado en 2014

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

artículo científico publicado en 2013

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

artículo científico publicado en 2002

Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study

artículo científico publicado en 2008

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

artículo científico publicado en 2016

Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG

artículo científico publicado en 2015

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).

artículo científico publicado en 2018

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).

artículo científico publicado en 2013

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

artículo científico publicado en 2014

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.

artículo científico publicado en 2006

Systemic Therapy for Women with ErbB2-Positive Breast Cancer: New Options, New Challenges ⬇️

artículo científico publicado el 26 de abril de 2010

Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.

artículo científico publicado en 2017

Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer

artículo científico publicado en 2017

Targeted Therapy for Early and Locally Advanced Breast Cancer ⬇️

artículo científico publicado el 16 de junio de 2010

Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy

artículo científico publicado en 2016

Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial

artículo científico publicado en 2017

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

artículo científico publicado en 2013

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

scientific article published on 01 November 2019

The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer

The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer.

artículo científico publicado en 2006

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

artículo científico publicado en 2019

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

artículo científico publicado en 2005

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

artículo científico publicado en 2015

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

artículo científico publicado en 2014

Treatment Modification in Young Breast Cancer Patients

artículo científico publicado en 2016

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry

artículo científico publicado en 2017

Treatment of Early Breast Cancer

artículo científico publicado en 2011

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers

artículo científico publicado en 2014

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

artículo científico publicado en 2017

Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study

artículo científico publicado en 2010

Two truncating variants in FANCC and breast cancer risk

artículo científico publicado en 2019

Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group

artículo científico

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.

artículo científico publicado en 2016

Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy

artículo científico publicado en 2015

Weeklynab-Paclitaxel in Metastatic Breast Cancer Summary and Results of an Expert Panel Discussion ⬇️

artículo científico publicado el 16 de abril de 2012

What is new in breast cancer? The expanding role of aromatase inhibitors.

artículo científico publicado en 2006

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

artículo científico publicado en 2009

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).

artículo científico publicado en 2016

[Multiparametric flow cytometry determination of the EGF receptor and DNA cell cycle distribution in cervix cancer]

scientific article published on 01 January 1993

[Prognostic value of tumor cells in bone marrow in breast cancer]

artículo científico publicado en 1993

[Testing chemosensitivity of cancer cell lines and gynecologic tumors with the ATP assay]

artículo científico publicado en 1993

[Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m2 KO) in the adjuvant and metastatic situation]

artículo científico publicado en 1993

pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda